AI Protein Design Advances, Yet Developability Remains Overlooked
Some new protein design competition results from Rio, showing the field keeps tackling harder and harder targets w/ AI methods Might be time to factor in other properties (developability, manufacturability)? https://t.co/h1niVwjnSS
Integrated Academic-Community Tumor Board Enhances Precision Medicine
Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine Molecular Tumor Board [MTB] [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO https://t.co/HOWIx826Lm https://t.co/1JmBdW6K5c
Molecular Tumor Boards Cut Costs, Reduce Recommendation Discordance
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChBGjx #PrecisionMedicine #hpeonc @Aurora_Cancer https://t.co/ZUQXq4npfh
Overcoming Barriers to Community Oncology Precision Medicine
Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices - @JLErsek @lorablk @mtmdphd & @EdKimMDLCI #ASCO18 Education Book https://t.co/ahsmfePatk #NCORP
BPL-003
Great piece from @Shea_ARK "AtaiBeckley is advancing BPL-003—an intra-nasal formulation derived from 5-MeO-DMT—in treatment-resistant depression, with positive Phase 2b results supporting a Phase 3 initiation in the second quarter of 2026.[11] With FDA Breakthrough Therapy designation, BPL-003 has the potential...
PurIST Classifier Validated for Tailored Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/KNJHtWovqT
Biliary Cancer Subtypes Show Distinct Immune Signatures
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5jvN #hpbcsm #PrecisionMedicine https://t.co/p3BzJ82oxA
BRAF Class II/III Mutations Represent Unmet Clinical Need
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson etal #ESMO2240P @TempusAI https://t.co/s5PEBEczlv @Annals_Oncology DOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
ASCO Endorses Somatic Genomic Testing for Advanced Cancers
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: @ASCO Provisional Clinical Opinion [Feb 17, 2022] @CDebyaniPhD et al. @JCO_ASCO https://t.co/hfHUBS3Unx #PrecisionMedicine https://t.co/GwYOMRD1hh
BRAFV600E‑mutated Pediatric Gliofibroma Shows Fleeting Therapy Response
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution [Mar 27, 2019] @KanevaMD et al. @JCOPO_ASCO https://t.co/oNbfrK7EZr #PrecisionMedicine #btsm https://t.co/V7k9vEiqKm
KRASG12C Mutations Linked to Distinct Immuno‑oncology Biomarkers
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers [Mar 23, 2022] @SalemGIOncDoc et al. @JCOPO_ASCO https://t.co/iehC82lyA4 #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/wZzfdnBoXU
Comprehensive Genomic Panel Broadens Community Oncology Treatment Options
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO https://t.co/tDi3kbxdvX #PrecisionMedicine #hemeonc @TempusAI https://t.co/6QKo7c3oH2
FDA Accuses Amgen of Data Manipulation; Erasca Falls
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results https://t.co/UbftjXwEwa $AMGN $ERAS - 53% $RCKT $JANX
AI Reads Retinal Images to Screen Multiple Diseases
What superhuman vision can detect from the retinal photo, which human eyes cannot, is stunning. A new foundation AI model screening for diabetes hypertension, hyperlipidemia, gout, osteoporosis, and thyroid disease @NatureMedicine https://t.co/GhKvUqz4Vy https://t.co/iKcXCbLceu
Pregnancy’s Progesterone: Natural Calm, Muscle Relaxant, Immune Tolerance
Ever notice how some pregnant women seem so calm, almost like they are in an altered state? That is progesterone. Progesterone rises dramatically during pregnancy. Outside of pregnancy, your progesterone levels are less than 1 ng/mL. During your luteal phase, it...
Anthocyanins Improve Cardiometabolic and Anti‑
Anthocyanin supplementation in adults at risk for dementia: a randomized controlled trial on its cardiometabolic and anti-inflammatory biomarker effects https://t.co/tHwVYQ3yvQ https://t.co/cxiRpkIj7W
Coultreon Secures $125M to Test Former Galapagos Immune Drug
Coultreon banks $125M to support testing of former Galapagos immune drug https://t.co/PUsEu2i7Vv by @Lilah_Alvarado $GLPG #biotech #startups
GLP‑1 Therapy Shows Benefit for Type 1 Diabetes Patients
A 174,000-patient analysis just delivered the first hard evidence that GLP-1 drugs work in a population every clinical trial has excluded. As a medical school professor, I teach that Type 1 diabetes is autoimmune, Type 2 is metabolic. But the cardiovascular...
Low‑cost Vaccines Delivered, Autism Genes
What a dishonest & ignorant thing to write, I develop low-cost vaccines for global health, 100 million doses administered, without patenting the technology. Also as I’ve detailed we’ve learned a lot about the genetic basis of autism, >100 autism genes,...
AstraZeneca's Bretzi Inhaler Cleared for Asthma in Teens
#AZN Bretzi inhaler approved by US FDA for treating patients 12 years old and upwards for Asthma, following the KALOS and LOGOS Phase III trials. Previously got COPD approval.
Morgan Stanley Flags IL‑23 Combos, Seeks Novel MOAs
Immunology combination studies from Morgan Stanley ahead of DUET data next week. These are mainly coformulations of established drugs, it would be more intriguing to see novel MOAs added to an IL23 backbone. https://t.co/dde8MpBhUR
Enhanced Exosomes Modulate OA Inflammatory Microenvironment
The role of exosomes and their enhancement strategies in the treatment of osteoarthritis "This article provides a comprehensive review and update on the research of exosomes, a type of extracellular vesicle, in the treatment of OA by modulating the inflammatory microenvironment..." https://t.co/xHjTCixJNE
Breakthrough Prize Showcases Baby Gene‑Editing Miracle
The 2026 Breakthrough Prize ceremony (“the Oscars for science”) celebrated the achievements of many remarkable scientists and their students and collaborators last weekend. Here’s the video of the show: https://t.co/eCHUnDqrYX. And here’s the segment in which Anne Hathaway and Alex...
10x Genomics Unveils A
I've been watching spatial biology for years. What @10xGenomics just announced changes the game. Serge Saxonov, CEO and Co-founder, 10x Genomics told Synbiobeta, "Biology is inherently complex, and as much progress as we have made, we still understand only a...
From Trial‑and‑Error to Predictive Cell‑Fate Engineering
We’re still engineering biology by trial and error. SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ18mc @MichaBreakstone is building a model to predict cell fate with his new...
Lithium Interaction Poses Major Seizure Risk with Psilocybin
Most physicians were never taught psilocybin in medical school. Their patients in three states can now legally access it. Oregon's program has been operating since summer 2023. Colorado's healing centers came online in 2025. New Mexico passed its Medical Psilocybin...
Autologous iPSC Dopamine Cells Boost Parkinson’s Function without Immunosuppression
I’ve been following @jeannefrances's work for years, and what @AspenNeuro just reported out of Copenhagen is the kind of result that changes a field. Twelve months after receiving their own reprogrammed dopamine neurons, eight Parkinson's patients are showing real, measurable...
ERAS-0015 Linked to Fatal Pneumonitis After Care Withdrawal
$ERAS safety update, from tonight's slides. One Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had...
Over Half of Gray Market Peptides Fail Quality Standards
New pre-print on gray market peptides using @finnrick_tests data: 41.6% to 71.1% of gray market peptide samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples. @Krysia830073
NIH Studies Often Ignore Sex Differences, Hindering Precision Medicine
Less than half of NIH-funded health studies analyze results by sex, potentially overlooking critical differences that impact diagnosis, treatment, and drug development for both men and women. precisionmedicine
Erasca Shows Promising 40% PDAC, 62% NSCLC Responses
$ERAS Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy $RVMD 40% uORR in PDAC; 62% uORR in NSCLC https://t.co/90BkD7tBeN
Early Bets on Consumer Bio and Dog Longevity Validated
ideas loyal had at our incipience that have been proven right 6 years later: 1. consumer bio 2. D2C marketing & distribution of drugs by the pharma co 3. dog owner demand for interventions (Rx, food, etc) to extend healthy lifespan 4....
Reta Won't Become All-Time Top-Selling Drug
Reta will not be the best selling drug of all time. Someone please remember this a decade from now.
Future Antidepressant Could Transform Millions Like Tirzepatide
Imagine a drug for reducing depression or anxiety that is as powerful as Tirzepatide is for reducing hunger. I think tens of millions of people will be on drugs like this in the next 5 years and I think it...
Eli Lilly Acquires Ajax to Strengthen JAK Pipeline
Lilly to buy startup Ajax in bid for a better JAK drug https://t.co/RMQQZ4mRFG $INCY $BMY $LLY $TAK #biotech #startups
Dispatch Biotherapeutics Launches First Clinical Trial
Remember Car June's new venture, Dispatch Biotherapeutics (raised $216 m since 2022)? Here's its first clinical trial: https://t.co/EIrZHSeHT8
Digital Twins Will Accelerate Drug Development via Virtual Trials
How digital twins and in silico clinical trials can change the future of drug development https://t.co/lEhJNwrSlH
ERAS Pan‑Ras Data Released; RVMD Alleges Patent Infringement
$ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents. https://t.co/QTmyUhT89n
T‑cell Engagers Need Missing Design Tricks for Success
With the rise and rise of ADCs, T cell engagers have taken something of a back seat of late. What if the bigger problem is some of them may be missing a key trick? Here we highlight some design...
NTLA's HAE Results Fall Short, Funding Needed for Weak Launch
$NTLA HAE study results were both expected and unimpressive relative to current treatments. The company will need to raise a lot of money to sell a therapy that is not going to launch well.
Unverified Tips Can Mislead: False Compass Data
Interesting side note on today's disappointing $CMPX results: Yesterday, I received a message on Signal from someone claiming to be a Compass employee. He gave me the purported tovecimig PFS and OS data. I didn't do anything with the supposedly material...
India Busts Massive Counterfeit Food and Drug Operation
🚨 INDIA EATING POISON 🚨 Delhi - Fake toothpaste factory: 1,800 filled tubes, 10,000 empty tubes, 1,200 packed units and 130kg of raw material of Sensodyne toothpaste. - Fake Eno sachets: 1 lakh. - Fake Nescafé sachets: 50,000. Ayodhya - 500 cartons of fake Fortune oil...
Fathom Therapeutics Secures $47M Series A for AI‑Physics Drug Discovery
Exclusive: Fathom Therapeutics, formerly Atommap, has raised a $47M Series A, building a pipeline with its strategy of blending AI and physics approaches to drug discovery: https://t.co/iAlmJwCQK7
CRISPR Therapy Cuts Swelling Attacks 87%, 60% Attack‑Free
$NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Attack rates dropped 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. https://t.co/ljPC7Lww0D via @Jasonmmast
NTLA's Attack Metrics Fall Short of Expectations
$NTLA 87% attack reduction and only 62% attack free rate. Attack free rate especially widely missed the bar set ahead of time by @GeneInvesting. Legitimately worse than I expected. https://t.co/wmNFYfsQSj
Oruka's Long-Acting Psoriasis Drug Achieves 63% PASI‑100
$ORKA Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study 63% PASI 100 score at 16 weeks, very strong data. https://t.co/RJxnbuU0e3 via me
Veradermics' Hair Loss Drug Clears Late-Stage Trial
Ok, here we go... $MANE Veradermics' hair loss drug succeeds in late-stage trial. A report from @ADeAngelis_bio https://t.co/jtSB36sPGO
Key Insights Await From Tovecimig Companion-002 Data
$CMPX data from Companion-002 study of tovecimig coming before 8am ET today. What to look out for, via @ByMadeleineA -> https://t.co/6IDCqMyNPE
FDA Approves Weekly Self‑Injectable Saphnelo for Lupus
#AZN Saphnelo for treating systemic lupus erythematosus, approved by US FDA for self-administration via a once a week autoinjector Pen.
Tesaro's Breach Claim Dismissed, Jemperli Licence Fight Persists
Looks like #GSK subsidiary TESARO Inc., has had a "claim for anticipatory breach" against AnaptysBio kicked out by Delaware Chancery Court. Principal contract dispute still ongoing though around Jemperli (Dostarlimab) licence agreement.